DE69634613D1 - Neue stabilisierte galenische Formulierungen enthaltend ein säureempfindliches Benzimidazol und Verfahren zu ihrer Herstellung - Google Patents
Neue stabilisierte galenische Formulierungen enthaltend ein säureempfindliches Benzimidazol und Verfahren zu ihrer HerstellungInfo
- Publication number
- DE69634613D1 DE69634613D1 DE69634613T DE69634613T DE69634613D1 DE 69634613 D1 DE69634613 D1 DE 69634613D1 DE 69634613 T DE69634613 T DE 69634613T DE 69634613 T DE69634613 T DE 69634613T DE 69634613 D1 DE69634613 D1 DE 69634613D1
- Authority
- DE
- Germany
- Prior art keywords
- preparation
- acid
- formulations containing
- galenic formulations
- novel stabilized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES9500181 | 1995-02-01 | ||
ES09500181A ES2094694B1 (es) | 1995-02-01 | 1995-02-01 | Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion. |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69634613D1 true DE69634613D1 (de) | 2005-05-19 |
DE69634613T2 DE69634613T2 (de) | 2006-03-09 |
Family
ID=8289322
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69634613T Revoked DE69634613T2 (de) | 1995-02-01 | 1996-01-26 | Neue stabilisierte galenische Formulierungen enthaltend ein säureempfindliches Benzimidazol und Verfahren zu ihrer Herstellung |
DE29623938U Expired - Lifetime DE29623938U1 (de) | 1995-02-01 | 1996-01-26 | Neue stabile galenische Formulierungen, enthaltend eine säureempfindliche Benzimidazolverbindung |
DE69608767T Revoked DE69608767D1 (de) | 1995-02-01 | 1996-01-26 | Neue stabile galenische formulierungen, die eine säurelabile benzimidazolverbindung enthalten, und herstellungsverfahren |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE29623938U Expired - Lifetime DE29623938U1 (de) | 1995-02-01 | 1996-01-26 | Neue stabile galenische Formulierungen, enthaltend eine säureempfindliche Benzimidazolverbindung |
DE69608767T Revoked DE69608767D1 (de) | 1995-02-01 | 1996-01-26 | Neue stabile galenische formulierungen, die eine säurelabile benzimidazolverbindung enthalten, und herstellungsverfahren |
Country Status (20)
Country | Link |
---|---|
US (1) | US5626875A (de) |
EP (2) | EP0993830B1 (de) |
JP (1) | JP4183746B2 (de) |
KR (1) | KR100331290B1 (de) |
AR (1) | AR002702A1 (de) |
AT (2) | ATE292967T1 (de) |
AU (1) | AU4540396A (de) |
CA (1) | CA2184842C (de) |
DE (3) | DE69634613T2 (de) |
DK (2) | DK0993830T3 (de) |
ES (3) | ES2094694B1 (de) |
FI (1) | FI121730B (de) |
HU (1) | HU229219B1 (de) |
IL (1) | IL116673A (de) |
IN (1) | IN186596B (de) |
PT (2) | PT773025E (de) |
SI (2) | SI0773025T1 (de) |
TW (1) | TW503115B (de) |
WO (1) | WO1996023500A1 (de) |
ZA (1) | ZA96683B (de) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9500478D0 (sv) * | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
PL186605B1 (pl) * | 1995-09-21 | 2004-01-30 | Pharma Pass Llc | Tabletka lub mikrotabletka zawierająca rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol oraz sposób wytwarzania tabletek lub mikrotabletek zawierających rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol |
SI9700186B (sl) | 1997-07-14 | 2006-10-31 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin |
ES2137862B1 (es) * | 1997-07-31 | 2000-09-16 | Intexim S A | Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion. |
US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
US6274591B1 (en) * | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
US6559158B1 (en) | 1997-11-03 | 2003-05-06 | Ur Labs, Inc. | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
FR2774288B1 (fr) † | 1998-01-30 | 2001-09-07 | Ethypharm Sa | Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques |
DK173431B1 (da) | 1998-03-20 | 2000-10-23 | Gea Farmaceutisk Fabrik As | Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs |
WO1999053918A1 (fr) | 1998-04-20 | 1999-10-28 | Eisai Co., Ltd. | Compositions stabilisees contenant des composes du type benzimidazole |
ZA9810765B (en) * | 1998-05-28 | 1999-08-06 | Ranbaxy Lab Ltd | Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole. |
PT1105105E (pt) * | 1998-08-12 | 2006-07-31 | Altana Pharma Ag | Forma de administracao oral para piridin-2-ilmetilsulfinil-1h-benzimidazois |
FR2793688B1 (fr) * | 1999-05-21 | 2003-06-13 | Ethypharm Lab Prod Ethiques | Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques |
ES2168043B1 (es) | 1999-09-13 | 2003-04-01 | Esteve Labor Dr | Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido. |
DE60036014T2 (de) | 1999-10-20 | 2008-04-30 | Eisai R&D Management Co., Ltd. | Methode zur stabilisierung von benzimidazol-verbindungen |
DE19959419A1 (de) * | 1999-12-09 | 2001-06-21 | Ratiopharm Gmbh | Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung |
DE69925740T2 (de) * | 1999-12-16 | 2006-05-11 | Laboratorio Medinfar-Produtos Farmacéuticos, S. A. | Neue stabile mehreinheitliche substituierte Benzimidazole enthaltende pharmazeutische Präparate |
US6419956B1 (en) * | 1999-12-30 | 2002-07-16 | Ancile Pharmaceuticals | Odor-masking coating for a pharmaceutical preparation |
AU2001296908A1 (en) * | 2000-09-29 | 2002-04-08 | Geneva Pharmaceuticals, Inc. | Proton pump inhibitor formulation |
AU2002219071A1 (en) * | 2000-11-10 | 2002-05-21 | F.Hoffman-La Roche Ag | Compositions containing hydrolytically unstable compositions |
WO2002098422A1 (en) * | 2001-06-05 | 2002-12-12 | University Of Chicago | Use of methylnaltrexone to treat immune suppression |
AU2002321204B2 (en) | 2001-07-16 | 2008-05-08 | Janssen Pharmaceutica N.V. | Improved process for preparing benzimidazole-type compounds |
NZ532568A (en) * | 2001-09-28 | 2005-07-29 | Mcneil Ppc Inc | Modified release dosage forms |
US20040170689A1 (en) * | 2001-11-09 | 2004-09-02 | Odink Debra Alida | Stabilized formulations comprising hydrolytically unstable compositions |
ES2198195B1 (es) | 2001-12-18 | 2004-10-01 | Laboratorios Del Dr. Esteve, S.A. | Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido. |
ES2299710T3 (es) * | 2002-08-02 | 2008-06-01 | Ratiopharm Gmbh | Preparacion farmaceutica que contiene un compuesto de bencimidazol mezclado con celulosa microcristalina y un metodo para su preparacion. |
US20040028737A1 (en) * | 2002-08-12 | 2004-02-12 | Kopran Research Laboratories Limited | Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same |
WO2004066982A1 (en) * | 2003-01-31 | 2004-08-12 | Ranbaxy Laboratories Limited | Stable oral benzimidazole compositions and processes for their preparation |
CN1767830A (zh) * | 2003-04-08 | 2006-05-03 | 普罗热尼奇制药公司 | 外周阿片拮抗剂具体是甲基纳曲酮治疗肠易激综合征的用途 |
CA2521420A1 (en) * | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist |
BRPI0409133B8 (pt) | 2003-04-08 | 2021-05-25 | Progenics Pharm Inc | preparações farmacêuticas estavéis compreendendo metilnaltrexona |
ES2234393B2 (es) * | 2003-04-29 | 2006-09-01 | Laboratorios Belmac, S.A. | "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido". |
AU2003245033A1 (en) * | 2003-05-08 | 2004-11-26 | Podili Khadgapathi | An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation |
WO2005011637A1 (ja) * | 2003-08-04 | 2005-02-10 | Eisai Co., Ltd. | 用時分散型製剤 |
TWI372066B (en) | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
AU2003272086A1 (en) * | 2003-10-14 | 2005-04-27 | Natco Pharma Limited | Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation |
GB0400781D0 (en) * | 2004-01-14 | 2004-02-18 | Novartis Ag | Organic compounds |
CN1964704A (zh) * | 2004-03-03 | 2007-05-16 | 特瓦制药工业有限公司 | 包含酸不稳定药物的稳定药用组合物 |
JP2007536349A (ja) | 2004-05-07 | 2007-12-13 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規の医薬剤形及び製造方法 |
US20050281876A1 (en) | 2004-06-18 | 2005-12-22 | Shun-Por Li | Solid dosage form for acid-labile active ingredient |
EP1830823A2 (de) | 2004-12-23 | 2007-09-12 | Ranbaxy Laboratories Limited | Stabile orale benzimidazol-zusammensetzungen und herstellungsverfahren |
EP1830822A1 (de) * | 2004-12-24 | 2007-09-12 | LEK Pharmaceuticals D.D. | Stabile pharmazeutische zusammensetzung mit einer wirksubstanz in form einer festen lösung |
US20090208575A1 (en) * | 2005-01-03 | 2009-08-20 | Lupin Limited | Pharmaceutical Composition Of Acid Labile Substances |
EP1845989A1 (de) * | 2005-01-20 | 2007-10-24 | Progenics Pharmaceuticals, Inc. | Verwendung von methylnaltrexon und damit zusammenhängenden verbindungen zur behandlung postoperativer gastrointestinaler dysfunktionen |
US20080279951A1 (en) * | 2005-02-02 | 2008-11-13 | Rajesh Gandhi | Stable Oral Benzimidazole Compositions Prepared by Non-Aqueous Layering Process |
US9662390B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8524731B2 (en) * | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
US8673352B2 (en) * | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
US7981908B2 (en) | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
US7803817B2 (en) * | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
AR057035A1 (es) * | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
US20080194611A1 (en) * | 2005-06-03 | 2008-08-14 | Alverdy John C | Modulation of Cell Barrier Dysfunction |
EP1785135A1 (de) | 2005-11-10 | 2007-05-16 | Laboratorios Del Dr. Esteve, S.A. | Neue Lanzoprazol enthaltende stabilisierte galenische Formulierungen und ihre Herstellung |
JP2009524592A (ja) * | 2005-12-20 | 2009-07-02 | テバ ファーマシューティカル インダストリーズ リミティド | ランソプラゾール経口崩壊錠剤 |
EP1813275A1 (de) * | 2005-12-20 | 2007-08-01 | Teva Pharmaceutical Industries Ltd | In der Mundhöle zerfallende Lansoprazol-Tabletten |
US7579476B2 (en) * | 2006-02-24 | 2009-08-25 | Praktikatalyst Pharma, Llc | Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals |
ITMI20061024A1 (it) * | 2006-05-25 | 2007-11-26 | Eurand Pharmaceuticals Ltd | Pellet a base di acido lipoico |
RU2467747C2 (ru) * | 2006-07-25 | 2012-11-27 | Векта Лтд. | Композиции и способы для ингибирования секреции желудочной кислоты с использованием производных малых дикарбоновых кислот в сочетании с ppi |
TW200817048A (en) * | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
JP2010522756A (ja) * | 2007-03-29 | 2010-07-08 | プロジェニックス ファーマシューティカルズ,インコーポレーテッド | 結晶形およびその使用 |
ES2540551T3 (es) * | 2007-03-29 | 2015-07-10 | Wyeth Llc | Antagonistas de receptores opioides periféricos y usos de los mismos |
WO2008121348A2 (en) * | 2007-03-29 | 2008-10-09 | Progenics Pharmaceuticals, Inc. | Peripheral opioid receptor antagonists and uses thereof |
WO2009099411A1 (en) | 2008-02-06 | 2009-08-13 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone |
US8911787B2 (en) | 2008-02-26 | 2014-12-16 | Ranbaxy Laboratories Limited | Stable oral benzimidazole compositions and process of preparation thereof |
CA2719134C (en) | 2008-03-21 | 2015-06-30 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
JP5985824B2 (ja) | 2008-07-01 | 2016-09-06 | ザ ユニヴァーシティー オヴ シカゴ | オピオイド受容体アンタゴニスト含有の粒子および使用方法 |
CA2733299A1 (en) * | 2008-08-11 | 2010-02-18 | Mepha Gmbh | Oral pharmaceutical formulation for omeprazole comprising a specific separation layer |
CH699302B1 (de) * | 2008-08-11 | 2012-03-15 | Mepha Gmbh | Orale pharmazeutische Formulierung für Omeprazol, enthaltend eine spezifische Trennschicht. |
CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
WO2010117756A2 (en) * | 2009-03-31 | 2010-10-14 | Dr. Reddy's Laboratories Ltd | Substituted benzimidazole pharmaceutical formulations |
US20130202688A1 (en) | 2010-05-04 | 2013-08-08 | Sunilendu Bhushan Roy | Delayed release oral disintegrating pharmaceutical compositions of lansoprazole |
ES2667402T3 (es) * | 2011-11-02 | 2018-05-10 | Laboratorios Del Dr. Esteve, S.A. | Composición farmacéutica de omeprazol |
GB2513172A (en) * | 2013-04-18 | 2014-10-22 | Nupharm Lab Ltd | Liquid dosage form and delivery system |
EP3206491B1 (de) | 2014-10-17 | 2019-11-27 | Salix Pharmaceuticals, Inc. | Verwendung von methylnaltrexon zur verringerung der tumorprogression |
EP3288556A4 (de) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Oral zerfallende zusammensetzungen |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
EP3292862A1 (de) | 2016-09-07 | 2018-03-14 | Sandoz Ag | Omeprazolformulierungen |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB829055A (en) * | 1958-02-07 | 1960-02-24 | Charles E Frosst And Company | Improvements in or relating to pharmaceutical preparations |
US4150111A (en) * | 1974-05-28 | 1979-04-17 | Allister Warren | Enteric coated magnesium chloride |
JPS5837285B2 (ja) * | 1975-05-29 | 1983-08-15 | カブシキガイシヤ ミドリジユウジ | チヨウナイカンセンシヨウチリヨウザイノセイゾウホウホウ |
JPS5598120A (en) * | 1979-01-16 | 1980-07-25 | Shin Etsu Chem Co Ltd | Preparation of drug having enteric coating |
US4470980A (en) * | 1980-03-07 | 1984-09-11 | Interx Research Corp. | Method of increasing oral absorption of β-lactam antibiotics |
US4377568A (en) * | 1981-08-12 | 1983-03-22 | Merck Sharp & Dohme (I.A.) Corp. | Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same |
JPS58208155A (ja) * | 1982-05-28 | 1983-12-03 | Sumitomo Electric Ind Ltd | 光伝送用ガラスフアイバの製造方法 |
JPS59193831A (ja) * | 1983-04-18 | 1984-11-02 | Sankyo Co Ltd | 腸溶性製剤の製造法 |
CA1327010C (en) * | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
US5026560A (en) * | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
JPH0768125B2 (ja) * | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | 酸不安定化合物の内服用製剤 |
IT1230576B (it) * | 1988-10-20 | 1991-10-28 | Angeli Inst Spa | Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon |
US5395611A (en) * | 1990-04-24 | 1995-03-07 | The Governors Of The University Of Alberta | Phenolic amine depigmenting and antimelanoma agents |
IT1241740B (it) * | 1990-06-22 | 1994-02-01 | Edi Bondioli | Protezione per una forcella di estremita' di un albero cardanico |
JP2773959B2 (ja) * | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
US5316772A (en) * | 1990-12-19 | 1994-05-31 | Solvay & Cie, S.A. (Societe Anonyme) | Bilayered oral pharmaceutical composition with pH dependent release |
US5232706A (en) * | 1990-12-31 | 1993-08-03 | Esteve Quimica, S.A. | Oral pharmaceutical preparation containing omeprazol |
YU48263B (sh) * | 1991-06-17 | 1997-09-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola |
EP0519144B1 (de) * | 1991-06-21 | 1997-08-13 | Ilsan Ilac Ve Hammaddeleri Sanayi A.S. | Neues galenisches Verfahren für Omeprazol enthaltende Pellets |
FR2692146B1 (fr) | 1992-06-16 | 1995-06-02 | Ethypharm Sa | Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention. |
AU4513393A (en) * | 1992-07-17 | 1994-02-14 | Astra Aktiebolag | Pharmaceutical composition containing antiulcer agent |
SE9402431D0 (sv) * | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
SE9500478D0 (sv) | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
-
1995
- 1995-02-01 ES ES09500181A patent/ES2094694B1/es not_active Expired - Fee Related
- 1995-04-27 US US08/429,689 patent/US5626875A/en not_active Expired - Lifetime
-
1996
- 1996-01-04 IL IL11667396A patent/IL116673A/xx not_active IP Right Cessation
- 1996-01-17 AR AR10105196A patent/AR002702A1/es not_active Application Discontinuation
- 1996-01-22 IN IN104CA1996 patent/IN186596B/en unknown
- 1996-01-26 SI SI9630226T patent/SI0773025T1/xx unknown
- 1996-01-26 DE DE69634613T patent/DE69634613T2/de not_active Revoked
- 1996-01-26 DE DE29623938U patent/DE29623938U1/de not_active Expired - Lifetime
- 1996-01-26 ES ES99116334T patent/ES2238796T3/es not_active Expired - Lifetime
- 1996-01-26 WO PCT/ES1996/000013 patent/WO1996023500A1/es not_active Application Discontinuation
- 1996-01-26 PT PT96901349T patent/PT773025E/pt unknown
- 1996-01-26 EP EP99116334A patent/EP0993830B1/de not_active Revoked
- 1996-01-26 TW TW085100946A patent/TW503115B/zh not_active IP Right Cessation
- 1996-01-26 JP JP52327896A patent/JP4183746B2/ja not_active Expired - Fee Related
- 1996-01-26 AT AT99116334T patent/ATE292967T1/de not_active IP Right Cessation
- 1996-01-26 HU HU9603014A patent/HU229219B1/hu not_active IP Right Cessation
- 1996-01-26 AT AT96901349T patent/ATE193649T1/de not_active IP Right Cessation
- 1996-01-26 CA CA002184842A patent/CA2184842C/en not_active Expired - Fee Related
- 1996-01-26 AU AU45403/96A patent/AU4540396A/en not_active Abandoned
- 1996-01-26 PT PT99116334T patent/PT993830E/pt unknown
- 1996-01-26 DE DE69608767T patent/DE69608767D1/de not_active Revoked
- 1996-01-26 SI SI9630710T patent/SI0993830T1/xx unknown
- 1996-01-26 KR KR1019960704702A patent/KR100331290B1/ko not_active IP Right Cessation
- 1996-01-26 ES ES96901349T patent/ES2148725T3/es not_active Expired - Lifetime
- 1996-01-26 DK DK99116334T patent/DK0993830T3/da active
- 1996-01-26 DK DK96901349T patent/DK0773025T3/da active
- 1996-01-26 EP EP96901349A patent/EP0773025B1/de not_active Revoked
- 1996-01-30 ZA ZA96683A patent/ZA96683B/xx unknown
- 1996-09-30 FI FI963916A patent/FI121730B/fi not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69634613D1 (de) | Neue stabilisierte galenische Formulierungen enthaltend ein säureempfindliches Benzimidazol und Verfahren zu ihrer Herstellung | |
DE69518031D1 (de) | Feste fettlösliche Zusammensetzung und Verfahren zu ihrer Herstellung | |
DE69504604D1 (de) | Verzweigte Organosiliciumverbindungen und Verfahren zu ihrer Herstellung | |
DE69634806D1 (de) | Substituierte heterocyclische Verbindungen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen | |
DE69833490D1 (de) | Orale pharmazeutische zusammensetzung enthaltend ein benzimidazolderivat mit antiulcus wirkung und verfahren zu seiner herstellung | |
DE69901804D1 (de) | Pharmazeutische formulierungen enthaltend ein 2[[(2-pyridinyl)methyl]sulfinyl]benzimidazol mit antiulcus wirkung und verfahren zur herstellung solcher formulierungen | |
DE69313024D1 (de) | Festkörperbildaufnahmeanordnung und Verfahren zu ihrer Herstellung | |
DE69623510D1 (de) | Celluloseacetatlösung und Verfahren zu ihrer Herstellung | |
DE69800419D1 (de) | Kapsel mit verlängerter Wirkstofffreisetzung und Verfahren zu ihrer Herstellung | |
DE69634528D1 (de) | Polyalkoxysiloxane und Verfahren zu deren Herstellung | |
DE69609699D1 (de) | Klathrat-Verbindungen und Verfahren zu ihrer Herstellung | |
DE69411604D1 (de) | Wirkstoffzusammensetzung und Verfahren zu ihrer Herstellung | |
DE69522372D1 (de) | Polyasparaginsäurederivate und Verfahren zu ihrer Herstellung | |
DE59608606D1 (de) | Cyclosprorin(e) enthaltende pharmazeutische zubereitung zur oralen applikation und verfahren zu ihrer herstellung | |
ATE193296T1 (de) | Maltitol zusammensetzung und verfahren zu ihrer herstellung | |
DE69625176D1 (de) | Camptothecin-derivate und verfahren zu ihrer herstellung | |
DE69619464D1 (de) | Siliciumhaltige Ladungstransportverbindungen und Verfahren zu ihrer Herstellung | |
DE69601613D1 (de) | Makromonomere mit hohem Säuregehalt und Verfahren zu deren Herstellung | |
ATE226082T1 (de) | Pharmazeutische zusammensetzungen aus dalfopristine und quinupristine und verfahren zu ihrer herstellung | |
DE69500978D1 (de) | Verzweigte Polyenen und Verfahren zu ihrer Herstellung | |
DE69502772D1 (de) | Baccatinderivate und Verfahren zu ihrer Herstellung | |
PT86971A (pt) | Benzimidazole verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
DE69705565D1 (de) | Farbstoffzusammensetzungen und Verfahren zu ihrer Herstellung | |
ATE341325T1 (de) | Eprosartan arginyl-ladungsneutralisationskomplex und verfahren zu dessen herstellung und verabreichung | |
DE69519713D1 (de) | Diaminoverbindungen und Verfahren zu ihrer Herstellung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8331 | Complete revocation |